Resurrection Health Care (RHC) was selected along with Chicago's major academic medical centers as a clinical center in a national breast cancer prevention study. The Study of Tamoxifen and Raloxifene (STAR) will include 22,000 women at increased risk of breast cancer to determine whether the osteoporosis prevention drug raloxifene is as effective as tamoxifen has proven to be in reducing the incidence of breast cancer.
RHC is seeking to enroll 200 women in the STAR project. Resurrection Medical Center (RMC), Our Lady of the Resurrection Medical Center (OLR) and Saint Francis Hospital (SFH) are currently participating in the study. Principal investigators are Myles P. Cunningham, M.D., at Saint Francis; Adrian Bianco, M.D., at RMC; and Maciej Drazkiewicz, M.D., at OLR.
To be eligible, participants must be postmenopausal and over the age of 35 with an increased risk of breast cancer as determined by their age, personal medical history, first degree relative (mother, sister, daughter) with diagnoses of breast cancer, age at first menstrual period and age a first live birth.
Periodic informational sessions on the STAR trail will be held at each RHC hospital. For additional information or to be considered for participation in the study at RHC, call toll-free 877-397-STAR (7827).